Pivotal bioVenture Partners Investment Advisor
Latest statistics and disclosures from Pivotal bioVenture Partners Investment Advisor's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PCVX, OCS, ARQT, EVMN, ZBIO, and represent 78.56% of Pivotal bioVenture Partners Investment Advisor's stock portfolio.
- Added to shares of these 3 stocks: EVMN (+$33M), MPLT (+$11M), IMNM.
- Started 2 new stock positions in MPLT, EVMN.
- Reduced shares in these 3 stocks: ARQT (-$22M), ZBIO (-$6.8M), OCS.
- Pivotal bioVenture Partners Investment Advisor was a net buyer of stock by $20M.
- Pivotal bioVenture Partners Investment Advisor has $259M in assets under management (AUM), dropping by 49.53%.
- Central Index Key (CIK): 0001844645
Tip: Access up to 7 years of quarterly data
Positions held by Pivotal bioVenture Partners Investment Advisor consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Pivotal bioVenture Partners Investment Advisor
Pivotal bioVenture Partners Investment Advisor holds 12 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Vaxcyte (PCVX) | 24.5 | $63M | 1.4M | 46.14 |
|
|
| Oculis Holding Ordinary Shares (OCS) | 17.7 | $46M | 2.3M | 19.97 |
|
|
| Arcutis Biotherapeutics (ARQT) | 15.3 | $40M | -35% | 1.4M | 29.04 |
|
| Evommune Com Shs (EVMN) | 12.8 | $33M | NEW | 1.9M | 17.12 |
|
| Zenas Biopharma (ZBIO) | 8.3 | $22M | -24% | 592k | 36.31 |
|
| Trevi Therapeutics (TRVI) | 6.1 | $16M | 1.3M | 12.52 |
|
|
| Immunome (IMNM) | 6.1 | $16M | +45% | 733k | 21.48 |
|
| Maplight Therapeutics (MPLT) | 4.2 | $11M | NEW | 611k | 17.57 |
|
| Bioage Labs (BIOA) | 3.3 | $8.6M | 653k | 13.23 |
|
|
| Recursion Pharmaceuticals In Cl A (RXRX) | 0.9 | $2.4M | 596k | 4.09 |
|
|
| Rallybio Corp (RLYB) | 0.6 | $1.6M | 2.4M | 0.69 |
|
|
| Bolt Biotherapeutics Com New (BOLT) | 0.2 | $517k | 95k | 5.47 |
|
Past Filings by Pivotal bioVenture Partners Investment Advisor
SEC 13F filings are viewable for Pivotal bioVenture Partners Investment Advisor going back to 2020
- Pivotal bioVenture Partners Investment Advisor 2025 Q4 filed Feb. 13, 2026
- Pivotal bioVenture Partners Investment Advisor 2025 Q3 filed Nov. 13, 2025
- Pivotal bioVenture Partners Investment Advisor 2025 Q2 filed Aug. 13, 2025
- Pivotal bioVenture Partners Investment Advisor 2025 Q1 filed May 14, 2025
- Pivotal bioVenture Partners Investment Advisor 2024 Q4 filed Feb. 13, 2025
- Pivotal bioVenture Partners Investment Advisor 2024 Q3 filed Nov. 13, 2024
- Pivotal bioVenture Partners Investment Advisor 2024 Q2 filed Aug. 13, 2024
- Pivotal bioVenture Partners Investment Advisor 2024 Q1 filed May 14, 2024
- Pivotal bioVenture Partners Investment Advisor 2023 Q4 filed Feb. 13, 2024
- Pivotal bioVenture Partners Investment Advisor 2023 Q3 filed Nov. 13, 2023
- Pivotal bioVenture Partners Investment Advisor 2023 Q2 filed Aug. 11, 2023
- Pivotal bioVenture Partners Investment Advisor 2023 Q1 filed May 12, 2023
- Pivotal bioVenture Partners Investment Advisor 2022 Q4 filed Feb. 13, 2023
- Pivotal bioVenture Partners Investment Advisor 2022 Q3 filed Nov. 10, 2022
- Pivotal bioVenture Partners Investment Advisor 2022 Q2 filed Aug. 12, 2022
- Pivotal bioVenture Partners Investment Advisor 2022 Q1 filed May 13, 2022